ÂÜÀòÂÒÂ×

Jeffrey P. Castelli is the Chief Portfolio Officer and Head of Gene Therapy at Amicus Therapeutics. Jeffrey has over 20 years of experience in the pharmaceutical industry, with a focus on strategic business and R&D decisions, market opportunity assessments, and product development strategies.

Castelli started their career as a Life Sciences Analyst at the University of Pennsylvania’s Center for Technology Transfer, where they worked on evaluating and commercializing new technologies. Jeffrey then spent a year as a Business Development Analyst at Neose Technologies, a publicly-traded biotech company specializing in protein therapeutics.

In 2001, Castelli joined Health Advances as a Manager. During their four years there, they worked with pharmaceutical, medical device, and diagnostics companies to help them develop implementation plans and assess market opportunities. Jeffrey also assisted in due diligence projects and partnerships for over 20 products across various therapeutic areas, including cardiovascular, oncology, genetic disease, and autoimmune indications. In 2005, they helped develop business plans for two venture-backed biotech companies in the oncology and genetic disease space.

Since joining Amicus Therapeutics in 2006, Castelli has played a key role in the company’s success in developing and commercializing treatments for rare diseases. Jeffrey has led the development of several groundbreaking gene therapies and overseen the launch of three FDA-approved products. Under their leadership, Amicus has become a leading global biotechnology company specializing in rare diseases.

Jeffrey P. Castelli earned their Ph.D. in Biology from the University of Pennsylvania. Jeffrey also holds a B.S. in Biology from West Chester University of Pennsylvania.

Their manager is John Crowley, Chairman & CEO. Some of their coworkers include Julie Yu - Chief Program Officer, Daphne Quimi - Chief Financial Officer, and Ellen S. Rosenberg - Chief Legal Officer.